2017 has been a busy year for the ECMC network.
The new 5 year review officially started in April. With the renewed agreement of the 5 co-funders (CRUK; NIHR: CSO; HCRW; HSC), and on the back of a successful international peer review, we welcomed Liverpool back in the adult network, and saw an expansion from 9 to 11 locations in the paediatric network, with Southampton and Cambridge joining as new centres.
Following interest expressed by centres across the ECMC network, a newly established ECMC Haematology Network Group, led by Cardiff ECMC, met for the first time on the 25th October in the Hammersmith Hospital, with seven centres represented.
A key objective of the group is to strengthen the representation of Haematology within the ECMC Network, with the goal of enhancing the clinical and scientific contributions by this discipline.
Dr David Pinato has been awarded with a Cancer Research UK Postdoctoral Bursary for his project - Phenotypic characterisation of the anti-tumour immune response following loco-regional therapy of hepatocellular carcinoma.
It has been yet another busy year for the Stratified Medicine Programme (SMP2) and the National Lung Matrix Trial (NLMT) so we would like to extend a huge thank you to all our colleagues for their continued hard work and support, as well as to all the patients and their families who signed up to this new, innovative trial.
The SMP2 and NLMT network have delivered a huge amount over 2017. Key highlights of this year include:
The winners of the 2017 Greater Manchester Clinical Research Awards were revealed during an evening of celebration on Thursday 9 November. Staff from across the region’s Trusts and GP practices gathered in Manchester city centre for the fifth-annual ceremony to toast excellence in health research delivery. Individuals and teams were rewarded for their efforts across 10 categories, while special awards were also presented to an extra four outstanding recipients.
The Cardiff ECMC has helped in bringing together expertise from two Welsh hospitals to deliver a new cancer treatment as part of a clinical trial.
For the first time, the Clinical Research Facility (CRF) at the University Hospital of Wales (UHW), Velindre Cancer Centre’s Clinical Trials Unit (CTU) and TC BioPharm Ltd. have joined forces to deliver a study looking into an immunotherapy treatment in patients with advanced cancers.
We are delighted to announce our current Expressions of Interest (EOI) call is open
The ECMC Combinations Alliance and the NIHR CRN Industry Alliance are collaborating to support access to multiple molecules from several of our partners. We invite researchers, from both the ECMC and NIHR networks, to submit novel proposals involving one or more of the novel agents tabled below in combination with standard of care chemotherapy, and/or radiotherapy, and/or another novel drug.